Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Notes Payables: 2022-2025

Historic Notes Payables for bioAffinity Technologies (BIAF) over the last 2 years, with Sep 2025 value amounting to $136,396.

  • bioAffinity Technologies' Notes Payables fell 48.93% to $136,396 in Q3 2025 from the same period last year, while for Sep 2025 it was $136,396, marking a year-over-year decrease of 48.93%. This contributed to the annual value of $171,669 for FY2024, which is N/A change from last year.
  • According to the latest figures from Q3 2025, bioAffinity Technologies' Notes Payables is $136,396, which was up 314.00% from $32,946 recorded in Q2 2025.
  • Over the past 5 years, bioAffinity Technologies' Notes Payables peaked at $325,000 during Q3 2022, and registered a low of $4,106 during Q2 2024.
  • In the last 2 years, bioAffinity Technologies' Notes Payables had a median value of $104,766 in 2025 and averaged $103,093.
  • Data for bioAffinity Technologies' Notes Payables shows a peak YoY increase of 2,135.72% (in 2025) and a maximum YoY decrease of 48.93% (in 2025) over the last 5 years.
  • Quarterly analysis of 3 years shows bioAffinity Technologies' Notes Payables stood at $325,000 in 2022, then reached $171,669 in 2024, then plummeted by 48.93% to $136,396 in 2025.
  • Its Notes Payables was $136,396 in Q3 2025, compared to $32,946 in Q2 2025 and $104,766 in Q1 2025.